Literature DB >> 15814075

Myoclonus.

Melissa J Nirenberg1, Steven J Frucht.   

Abstract

Myoclonus is defined as sudden, brief, shock-like involuntary movements affecting one or more muscles. The term encompasses a wide range of different physiologic and pathologic processes. When evaluating a patient with myoclonus, the first step is to identify the underlying etiology. Initial treatment should be directed against any underlying toxic or metabolic conditions. Next, targeted pharmacotherapy should be chosen, principally on the basis of the probable anatomical localization. Although treatment is initiated with a single agent, polytherapy usually is necessary to achieve adequate symptomatic control. The prognosis of myoclonus is highly variable, and largely depends on the underlying cause.

Entities:  

Year:  2005        PMID: 15814075     DOI: 10.1007/s11940-005-0015-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  22 in total

1.  Neurostimulation of the ventral intermediate thalamic nucleus alleviates hereditary essential myoclonus.

Authors:  A Kupsch; T Trottenberg; W Meissner; T Funk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Myoclonus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Amelioration of spinal myoclonus with levetiracetam.

Authors:  S C Keswani; E H Kossoff; G L Krauss; C Hagerty
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 4.  Zonisamide.

Authors:  I E Leppik
Journal:  Epilepsia       Date:  1999       Impact factor: 5.864

Review 5.  Newer antiepileptic drugs: advantages and disadvantages.

Authors:  S J Wallace
Journal:  Brain Dev       Date:  2001-08       Impact factor: 1.961

6.  Involvement of the medial pallidum in focal myoclonic dystonia: A clinical and neurophysiological case study.

Authors:  Xuguang Liu; Ivan C Griffin; Simon G Parkin; R Christopher Miall; Jeremy G Rowe; Ralph P Gregory; Richard B Scott; Tipu Z Aziz; John F Stein
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

7.  Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.

Authors:  G L Krauss; A Bergin; R E Kramer; Y W Cho; S G Reich
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

8.  Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.

Authors:  M Koskiniemi; B Van Vleymen; L Hakamies; S Lamusuo; J Taalas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

9.  Acetazolamide therapy improves action myoclonus in Ramsay Hunt Syndrome.

Authors:  S M Baig
Journal:  J Neurol Sci       Date:  1997-01       Impact factor: 3.181

10.  Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate.

Authors:  K Easterford; P Clough; M Kellett; K Fallon; S Duncan
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

View more
  2 in total

1.  Emergency treatment of movement disorders.

Authors:  Shu-Ching Hu; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

2.  Looking "Cherry Red Spot Myoclonus" in the Eyes: Clinical Phenotype, Treatment Response, and Eye Movements in Sialidosis Type 1.

Authors:  Giulietta M Riboldi; John Martone; John-Ross Rizzo; Todd E Hudson; Janet C Rucker; Steven J Frucht
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2021-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.